A Phase 1 interventional study of AG-013736 and AG-013736 in Hepatic Insufficiency, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-04-11.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Hepatic Insufficiency with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Hepatic Insufficiency · United States.
Among the 52 studies in Hepatic Insufficiency with a site in United States, this one is the 30th largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2008, is one of 42 in phase 1, and was the 7th registered.
113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.
Browse Hepatic Insufficiency studies →3 of the 52 studies in Hepatic Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+ · Healthy volunteers
Incyte Corporation · Sites in United States
Ages 18–80
Eli Lilly and Company · Sites in United States, Hungary
Ages 18–85 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 29 across 100 interventional studies indexed under Hepatic Insufficiency.
Median enrollment 28 across the 48 interventional studies, 28 across the 3 observational. Of the 47 that completed or were terminated, 16 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 52 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 6 studies filed under Hepatic Insufficiency — fewer than ten, so there is no comparison to draw.
3 of the studies in Hepatic Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07401862Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. | 2027-03 |
| NCT07559474Incyte CorporationA Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment | 2027-04-13 |
| NCT07677358PfizerA Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease | 2027-08-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 52 studies in Hepatic Insufficiency with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effects of mild and moderate impairment of hepatic function on the single-dose pharmacokinetics, safety and tolerability of AG-013736.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with mild hepatic impairment (Child Pugh class A, score 5-6)
Drug: AG-013736
Subjects with moderate hepatic impairment(Child Pugh class B,score 7-9)
Drug: AG-013736
Group 1 1) subjects with normal hepatic function
Drug: AG-013736
Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
Maximum Observed Plasma Concentration (Cmax)
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hours (hrs) post-dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Plasma Elimination Half-life (t1/2)
Plasma elimination half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Apparent Oral Clearance (CL/F)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Apparent Volume of Distribution (Vz/F)
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the oral bioavailability.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Fraction of Unbound Drug (fu)
Fraction of unbound drug (fu) is defined as the ratio of unbound drug concentration to the total drug concentration.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Unbound Apparent Oral Clearance (CLu/F)
Clearance of an unbound drug is a measure of the rate at which an unbound drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability. Unbound drug clearance is a quantitative measure of the rate at which an unbound drug substance is removed from the blood.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Unbound Apparent Volume of Distribution (Vzu/F)
Volume of distribution of unbound drug is defined as the theoretical volume in which the total amount of unbound drug would need to be uniformly distributed to produce the desired plasma concentration of unbound drug. Unbound apparent volume of distribution after oral dose (Vzu/F) is influenced by the oral bioavailability.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Unbound Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)u]
AUC (0 - ∞)u = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞) for unbound drug. It is obtained from AUCu (0 - t) plus AUCu (t - ∞).
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Unbound Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClastu)
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClastu) for unbound drug.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Unbound Maximum Observed Plasma Concentration (Cmaxu)
Cmaxu is the highest measured unbound plasma concentration during the dosing interval.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
| Milestone | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment |
|---|---|---|---|
| Started | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 |
| ng/mL | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 30.43 ± 50.00 | 26.96 ± 127.00 | 38.85 ± 50.00 |
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
| ng*hr/mL | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment |
|---|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] | 155.68 ± 63.00 | 121.96 ± 167.00 | 303.96 ± 44.00 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
| ng*hr/mL | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment |
|---|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) | 148.43 ± 69.00 | 115.98 ± 180.00 | 295.23 ± 44.00 |
| hr | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment |
|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 3.50 (2.00 to 4.00) | 2.75 (1.00 to 4.00) | 4.00 (1.50 to 4.00) |
Plasma elimination half-life is the time measured for the plasma concentration to decrease by one half.
| hr | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment |
|---|---|---|---|
| Plasma Elimination Half-life (t1/2) | 4.74 ± 3.77 | 3.61 ± 3.02 | 7.12 ± 6.49 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| mL/min | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment |
|---|---|---|---|
| Apparent Oral Clearance (CL/F) | 535.3 ± 63.0 | 683.3 ± 167.0 | 274.2 ± 44.0 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the oral bioavailability.
| Liter (L) | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment |
|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) | 166.43 ± 52.00 | 162.65 ± 87.00 | 127.68 ± 67.00 |
Fraction of unbound drug (fu) is defined as the ratio of unbound drug concentration to the total drug concentration.
| Ratio | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment |
|---|---|---|---|
| Fraction of Unbound Drug (fu) | 0.004 ± 25.000 | 0.003 ± 50.000 | 0.004 ± 134.000 |
Clearance of an unbound drug is a measure of the rate at which an unbound drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability. Unbound drug clearance is a quantitative measure of the rate at which an unbound drug substance is removed from the blood.
| mL/min | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment |
|---|---|---|---|
| Unbound Apparent Oral Clearance (CLu/F) | 132218.6 ± 56.0 | 120883.5 ± 82.0 | 67143.1 ± 109.0 |
Volume of distribution of unbound drug is defined as the theoretical volume in which the total amount of unbound drug would need to be uniformly distributed to produce the desired plasma concentration of unbound drug. Unbound apparent volume of distribution after oral dose (Vzu/F) is influenced by the oral bioavailability.
| L | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment |
|---|---|---|---|
| Unbound Apparent Volume of Distribution (Vzu/F) | 41108.6 ± 57.0 | 42378.3 ± 40.0 | 31268.8 ± 121.0 |
AUC (0 - ∞)u = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞) for unbound drug. It is obtained from AUCu (0 - t) plus AUCu (t - ∞).
| ng*hr/mL | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment |
|---|---|---|---|
| Unbound Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)u] | 0.63 ± 56.00 | 0.69 ± 82.00 | 1.24 ± 109.00 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClastu) for unbound drug.
| ng*hr/mL | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment |
|---|---|---|---|
| Unbound Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClastu) | 0.60 ± 61.00 | 0.67 ± 81.00 | 1.21 ± 106.00 |
Cmaxu is the highest measured unbound plasma concentration during the dosing interval.
| ng/mL | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment |
|---|---|---|---|
| Unbound Maximum Observed Plasma Concentration (Cmaxu) | 0.12 ± 46.00 | 0.13 ± 47.00 | 0.16 ± 97.00 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib : Normal Hepatic Function | — | 0/8 (0%) | 3/8 (37.5%) |
| Axitinib : Mild Hepatic Impairment | — | 0/8 (0%) | 0/8 (0%) |
| Axitinib : Moderate Hepatic Impairment | — | 0/8 (0%) | 0/8 (0%) |
| Event | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment |
|---|---|---|---|
| LethargyNervous system disorders | 3/8 | 0/8 | 0/8 |
| HeadacheNervous system disorders | 1/8 | 0/8 | 0/8 |
| Age Continuous(years) | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment | Total |
|---|---|---|---|---|
| Mean | 47.4 ± 5.2 | 52.5 ± 5.6 | 54.3 ± 4.7 | 51.4 ± 5.8 |
| Sex: Female, Male(Participants) | Axitinib : Normal Hepatic Function | Axitinib : Mild Hepatic Impairment | Axitinib : Moderate Hepatic Impairment | Total |
|---|---|---|---|---|
| Female | 1 | 1 | 2 | 4 |
| Male | 7 | 7 | 6 | 20 |
The record gives a start of May 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib